231 related articles for article (PubMed ID: 33664388)
1. Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.
Andereggen L; Frey J; Andres RH; Luedi MM; Widmer HR; Beck J; Mariani L; Christ E
Sci Rep; 2021 Mar; 11(1):5122. PubMed ID: 33664388
[TBL] [Abstract][Full Text] [Related]
2. [Prolactinomas and bone mineral density in men].
Naliato EC; Farias ML; Violante AH
Arq Bras Endocrinol Metabol; 2005 Apr; 49(2):183-95. PubMed ID: 16184246
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
World Neurosurg; 2017 Jan; 97():595-602. PubMed ID: 27773859
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of osteopenia in men with prolactinoma.
Naliato EC; Farias ML; Braucks GR; Costa FS; Zylberberg D; Violante AH
J Endocrinol Invest; 2005 Jan; 28(1):12-7. PubMed ID: 15816365
[TBL] [Abstract][Full Text] [Related]
5. Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men.
Rudman Y; Duskin-Bitan H; Richter I; Tsvetov G; Masri-Iraqi H; Akirov A; Shimon I
Andrology; 2023 Oct; 11(7):1398-1407. PubMed ID: 36897756
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and magnitude of osteopenia in patients with prolactinoma.
Kayath MJ; Lengyel AM; Vieira JG
Braz J Med Biol Res; 1993 Sep; 26(9):933-41. PubMed ID: 8298528
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density and bone turnover in hyperprolactinaemia of various origins.
Zadrozna-Sliwka B; Bolanowski M; Kałuzny M; Syrycka J
Endokrynol Pol; 2007; 58(2):116-22. PubMed ID: 17578827
[TBL] [Abstract][Full Text] [Related]
8. Vertebral fractures in males with prolactinoma.
Mazziotti G; Porcelli T; Mormando M; De Menis E; Bianchi A; Mejia C; Mancini T; De Marinis L; Giustina A
Endocrine; 2011 Jun; 39(3):288-93. PubMed ID: 21479837
[TBL] [Abstract][Full Text] [Related]
9. Bone loss associated with hyperprolactinemia in patients with schizophrenia.
Kinon BJ; Liu-Seifert H; Stauffer VL; Jacob J
Clin Schizophr Relat Psychoses; 2013 Oct; 7(3):115-23. PubMed ID: 23395836
[TBL] [Abstract][Full Text] [Related]
10. [Decreased bone mineral density in pre-menopause women with prolactinoma].
Bussade I; Naliato EC; Mendonça LM; Violante AH; Farias ML
Arq Bras Endocrinol Metabol; 2007 Dec; 51(9):1522-7. PubMed ID: 18209896
[TBL] [Abstract][Full Text] [Related]
11. Effects of hyperprolactinemia on osteoporotic fracture risk in premenopausal women.
Vartej P; Poiana C; Vartej I
Gynecol Endocrinol; 2001 Feb; 15(1):43-7. PubMed ID: 11293923
[TBL] [Abstract][Full Text] [Related]
12. Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study.
Posawetz AS; Trummer C; Pandis M; Aberer F; Pieber TR; Obermayer-Pietsch B; Pilz S; Theiler-Schwetz V
BMC Endocr Disord; 2021 Apr; 21(1):81. PubMed ID: 33902531
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia diagnosis in elderly men: a cohort of 28 patients over 65 years.
Shimon I; Hirsch D; Tsvetov G; Robenshtok E; Akirov A; Fraenkel M; Eizenberg Y; Herzberg D; Barzilay-Yoseph L; Livner A; Friedrich I; Manisterski Y; Ishay A; Yoel U; Masri H
Endocrine; 2019 Sep; 65(3):656-661. PubMed ID: 31154607
[TBL] [Abstract][Full Text] [Related]
14. Treatment of hyperprolactinemia in post-menopausal women: pros.
Iacovazzo D; De Marinis L
Endocrine; 2015 Feb; 48(1):76-8. PubMed ID: 25112228
[TBL] [Abstract][Full Text] [Related]
15. Osteoporosis in men with hyperprolactinemic hypogonadism.
Greenspan SL; Neer RM; Ridgway EC; Klibanski A
Ann Intern Med; 1986 Jun; 104(6):777-82. PubMed ID: 3706929
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
O'Keane V
J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
[TBL] [Abstract][Full Text] [Related]
17. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip J; Salvatori R; Yenokyan G; Wand GS
J Clin Endocrinol Metab; 2009 Jul; 94(7):2428-36. PubMed ID: 19336508
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinaemia in males: a heterogeneous disorder.
Walsh JP; Pullan PT
Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
[TBL] [Abstract][Full Text] [Related]
20. Prospective, long-term study of the effect of cabergoline on valvular status in patients with prolactinoma and idiopathic hyperprolactinemia.
Vroonen L; Lancellotti P; Garcia MT; Dulgheru R; Rubio-Almanza M; Maiga I; Magne J; Petrossians P; Auriemma R; Daly AF; Beckers A
Endocrine; 2017 Jan; 55(1):239-245. PubMed ID: 27709470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
